Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELGN-2112 versus placebo for intestinal malabsorption in preterm infants
NL-OMON59350Phase 3Recruiting
- Sponsor
- Elgan Pharma
- Start
- Jun 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in intestinal malabsorption comparing ELGN-2112 with Placebo (2 arms). Primary endpoint: Days to full enteral feeding. Started Jun 2025; status: recruiting.
02
Drugs
elgn-gi
03
Conditions
intestinal malabsorption
Beyond the preview
Go deeper on NL-OMON59350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59350.